Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-fv566 Total loading time: 0 Render date: 2024-07-18T21:30:26.886Z Has data issue: false hasContentIssue false

Chapter 48 - Allogeneic Hematopoietic Cell Transplants for Plasma Cell Myeloma

from Section 13 - Plasma Cell Dyscrasias: Hematopoietic Cell Transplants

Published online by Cambridge University Press:  24 May 2017

By
Thomas Giever  and
Parameswaran Hari
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 468 - 476
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Pasquini, MC Wang, Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2012. Available at: http://www.cibmtr.org. (Accessed March 30, 2013).Google Scholar
Bensinger, WI, Buckner, CD, Anasetti, C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2787–93.CrossRefGoogle ScholarPubMed
Gahrton, G, Tura, S, Flesch, M, et al. Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry. Hematol Oncol 1988;6:181–6.CrossRefGoogle Scholar
Gahrton, G, Tura, S, Ljungman, P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 1991;325:1267–73.CrossRefGoogle Scholar
Gahrton, G, Tura, S, Ljungman, P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995;13:1312–22.CrossRefGoogle ScholarPubMed
Barlogie, B, Kyle, RA, Anderson, KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929–36.CrossRefGoogle ScholarPubMed
Kroger, N, Schwerdtfeger, R, Kiehl, M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002;100:755–60.CrossRefGoogle ScholarPubMed
Giralt, S, Estey, E, Albitar, M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531–6.CrossRefGoogle ScholarPubMed
Bacigalupo, A, Ballen, K, Rizzo, D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15:1628–33.CrossRefGoogle ScholarPubMed
Maloney, DG, Molina, AJ, Sahebi, F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003;102:3447–54.CrossRefGoogle ScholarPubMed
Kroger, N, Sayer, HG, Schwerdtfeger, R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002;100:3919–24.CrossRefGoogle ScholarPubMed
Rotta, M, Storer, BE, Sahebi, F, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009;113:3383–91.CrossRefGoogle ScholarPubMed
Bruno, B, Rotta, M, Patriarca, F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009;113:3375–82.CrossRefGoogle ScholarPubMed
Kumar, S, Zhang, MJ, Li, P, et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood 2011;118:1979–88.CrossRefGoogle ScholarPubMed
Bruno, B, Rotta, M, Patriarca, F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110–20.CrossRefGoogle ScholarPubMed
Giaccone, L, Storer, B, Patriarca, F, et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011;117:6721–7.CrossRefGoogle ScholarPubMed
Krishnan, A, Pasquini, MC, Logan, B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011;12:1195–203.CrossRefGoogle ScholarPubMed
Gahrton, G, Iacobelli, S, Bjorkstrand, B, et al. Autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013;121:5055–63.CrossRefGoogle Scholar
Bjorkstrand, B, Iacobelli, S, Hegenbart, U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011;29:3016–22.CrossRefGoogle ScholarPubMed
Armeson, KE, Hill, EG, Costa, LJ. Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment. Bone Marrow Transplant 2013;48:562–7.CrossRefGoogle ScholarPubMed
Moreau, P, Garban, F, Attal, M, et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allo-HCTation with autologous transplantation in high-risk de novo multiple myeloma. Blood 2008;112:3914–5.Google ScholarPubMed
Stewart, AK. Reduced-intensity allogeneic transplantation for myeloma: reality bites. Blood 2009;113:3135–6.CrossRefGoogle ScholarPubMed
Weiden, PL, Sullivan, KM, Flournoy, N, Storb, R, Thomas, ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304:1529–33.CrossRefGoogle ScholarPubMed
Sullivan, KM, Fefer, A, Witherspoon, R, et al. Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. Prog Clin Biol Res 1987;244:391–9.Google ScholarPubMed
Horowitz, MM, Gale, RP, Sondel, PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–62.CrossRefGoogle ScholarPubMed
Kwak, LW, Taub, DD, Duffey, PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995;345:1016–20.CrossRefGoogle ScholarPubMed
Salama, M, Nevill, T, Marcellus, D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000;26:1179–84.CrossRefGoogle ScholarPubMed
Verdonck, LF, Lokhorst, HM, Dekker, AW, Nieuwenhuis, HK, Petersen, EJ. Graft-versus-myeloma effect in two cases. Lancet 1996;347:800–1.CrossRefGoogle ScholarPubMed
Lokhorst, HM, Schattenberg, A, Cornelissen, JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000;18:3031–7.CrossRefGoogle ScholarPubMed
van de Donk, NW, Kroger, N, Hegenbart, U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37:1135–41.CrossRefGoogle ScholarPubMed
Ringden, O, Shrestha, S, da Silva, GT, et al. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant 2012;47:831–7.CrossRefGoogle ScholarPubMed
Garban, F, Attal, M, Michallet, M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474–80.CrossRefGoogle Scholar
Alyea, E, Weller, E, Schlossman, R, et al. T-cell–depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001;98:934–9.CrossRefGoogle ScholarPubMed
Neben, K, Lokhorst, HM, Jauch, A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119:940–8.CrossRefGoogle ScholarPubMed
Avet-Loiseau, H, Daviet, A, Brigaudeau, C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001;97:822–5.CrossRefGoogle Scholar
Mikhael, JR, Dingli, D, Roy, V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc 2013;88:360–76.CrossRefGoogle ScholarPubMed
Mateos, M, Oriol, A, Martínez-López, J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. The Lancet Oncology 2010;11:934–41.CrossRefGoogle ScholarPubMed
Sonneveld, P, Schmidt-Wolf, IG, van der Holt, B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012;30:2946–55.CrossRefGoogle ScholarPubMed
Chang, H, Qi, X, Yeung, J, Reece, D, Xu, W, Patterson, B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 2009;33:259–62.CrossRefGoogle ScholarPubMed
Tiedemann, RE, Gonzalez-Paz, N, Kyle, RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22:1044–52.CrossRefGoogle ScholarPubMed
Bahlis, NJ. Darwinian evolution and tiding clones in multiple myeloma. Blood 2012;120:927–8.CrossRefGoogle ScholarPubMed
Egan, JB, Shi, CX, Tembe, W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012;120:1060–6.CrossRefGoogle ScholarPubMed
Michallet, M, Sobh, M, El-Cheikh, J, et al. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. Exp Hematol 2013;41:1008–15.CrossRefGoogle ScholarPubMed
Avet-Loiseau, H. Ultra high-risk myeloma. Hematology Am Soc Hematol Educ Program 2010;2010:489–93.Google ScholarPubMed
Kroger, N, Badbaran, A, Zabelina, T, et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2013;19:398–404.CrossRefGoogle ScholarPubMed
Knop, S, Liebisch, P, Hebart, H, et al. Autologous followed by allogeneic versus tandem-autologous stem cell transplant in newly diagnosed FISH-del13q myeloma. ASH Annual Meeting Abstracts 2014;124:43.Google Scholar
Kroger, N, Shimoni, A, Schilling, G, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol 2010;148:323–31.CrossRefGoogle ScholarPubMed
Freytes, CO, Vesole, DH, Zhong, X, et al. Second transplants in relapsed multiple myeloma (MM): autologous (AUTO-HCT) versus non-myeloablative/reduced intensity (NST/RIC) allogeneic transplantation (AlloHCT). ASH Annual Meeting Abstracts 2011;118:824.Google Scholar
Mehta, J, Tricot, G, Jagannath, S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998;21:887–92.CrossRefGoogle ScholarPubMed
Bashir, Q, Khan, H, Orlowski, RZ, et al. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2012;87:272–6.CrossRefGoogle ScholarPubMed
Lee, CK, Barlogie, B, Zangari, M, et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002;30:873–8.CrossRefGoogle ScholarPubMed
Jimenez-Zepeda, VH, Dominguez, VJ. Plasma cell leukemia: a rare condition. Ann Hematol 2006;85:263–7.CrossRefGoogle ScholarPubMed
Garcia-Sanz, R, Orfao, A, Gonzalez, M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999;93:1032–7.CrossRefGoogle ScholarPubMed
Chaoui, D, Leleu, X, Roussel, M, Royer, B, Rubio, MT, Ducastelle, S, et al. Has the prognostic of primary plasma cell leukemia improved with new drugs? ASH Annual Meeting Abstracts 2009;114:3869.Google Scholar
Drake, MB, Iacobelli, S, van Biezen, A, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica 2010;95:804–9.CrossRefGoogle ScholarPubMed
Mahindra, A, Kalaycio, ME, Vela-Ojeda, J, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012;26:1091–7.CrossRefGoogle ScholarPubMed
Gonsalves, WI, Rajkumar, SV, Go, RS, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 2014;124:907–12.CrossRefGoogle ScholarPubMed
Nishihori, T, Abu Kar, SM, Baz, R, et al. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013;19:1144–51.CrossRefGoogle ScholarPubMed
McCarthy, PL, Owzar, K, Hofmeister, CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770–81.CrossRefGoogle ScholarPubMed
Wolschke, C, Stubig, T, Hegenbart, U, et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. Exp Hematol 2013;41:134–142 e3.CrossRefGoogle Scholar
Luptakova, K, Rosenblatt, J, Glotzbecker, B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 2013;62:39–49.CrossRefGoogle ScholarPubMed
Rosenblatt, J, Vasir, B, Uhl, L, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011;117:393–402.CrossRefGoogle ScholarPubMed
Coman, T, Bachy, E, Michallet, M, et al. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the SFGM-TC. Haematologica 2013;98:776–83.CrossRefGoogle Scholar
Kneppers, E, van der Holt, B, Kersten, MJ, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011;118:2413–9.CrossRefGoogle Scholar
Alsina, M, Becker, P, Zhong, X, et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20:1183–9.CrossRefGoogle ScholarPubMed
Vodanovic-Jankovic, S, Hari, P, Jacobs, P, Komorowski, R, Drobyski, WR. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006;107:827–34.CrossRefGoogle ScholarPubMed
Koreth, J, Stevenson, KE, Kim, HT, et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 2012;30:3202–8.CrossRefGoogle ScholarPubMed
Kroger, N, Zabelina, T, Ayuk, F, et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006;34:770–5.CrossRefGoogle ScholarPubMed
Martinelli, G, Terragna, C, Zamagni, E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000;18:2273–81.CrossRefGoogle ScholarPubMed
Cavo, M, Terragna, C, Martinelli, G, et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000;96:355–7.CrossRefGoogle ScholarPubMed
Corradini, P, Cavo, M, Lokhorst, H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003;102:1927–9.CrossRefGoogle ScholarPubMed
Rawstron, AC, Davies, FE, DasGupta, R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095–100.CrossRefGoogle ScholarPubMed
Martinez-Lopez, J, Lahuerta, JJ, Pepin, F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014;123:2073–9.CrossRefGoogle ScholarPubMed
Paiva, B, Martinez-Lopez, J, Vidriales, MB, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011;29:1627–33.CrossRefGoogle ScholarPubMed
El-Cheikh, J, Crocchiolo, R, Boher, JM, et al. Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma. Eur J Haematol 2012;88:497–503.CrossRefGoogle ScholarPubMed
Kroger, N, Kruger, W, Renges, H, et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001;112:421–3.CrossRefGoogle ScholarPubMed
Lokhorst, HM, Wu, K, Verdonck, LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004;103:4362–4.CrossRefGoogle ScholarPubMed
Bellucci, R, Alyea, EP, Weller, E, et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood 2002;99:4610–7.CrossRefGoogle ScholarPubMed
de Carvalho, F, Alves, VL, Braga, WM, Xavier, CV Jr, Colleoni, GW. MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. Cancer Immunol Immunother 2013;62:191–5.CrossRefGoogle ScholarPubMed
Tyler, EM, Jungbluth, AA, O’Reilly, RJ, Koehne, G. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood 2013;121:308–17.CrossRefGoogle ScholarPubMed
Haessler, J, Shaughnessy, JD Jr, Zhan, F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007;13:7073–9.CrossRefGoogle ScholarPubMed
Hoering, A, Crowley, J, Shaughnessy, JD Jr, et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood 2009;114:1299–305.CrossRefGoogle ScholarPubMed
Rosinol, L, Perez-Simon, JA, Sureda, A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008;112:3591–3.CrossRefGoogle ScholarPubMed
Lokhorst, HM, van der Holt, B, Cornelissen, JJ, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012;119:6219,25; quiz 6399.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×